CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26 | +44.4% | 582 | +80.7% | 0.00% | – |
| Q2 2023 | $18 | +80.0% | 322 | +50.5% | 0.00% | – |
| Q1 2023 | $10 | -23.1% | 214 | -32.3% | 0.00% | – |
| Q4 2022 | $13 | -100.0% | 316 | -22.0% | 0.00% | – |
| Q3 2022 | $26,000 | -31.6% | 405 | -35.8% | 0.00% | – |
| Q2 2022 | $38,000 | -97.8% | 631 | -97.7% | 0.00% | -100.0% |
| Q1 2022 | $1,731,000 | -28.1% | 27,580 | -13.2% | 0.01% | -29.4% |
| Q4 2021 | $2,407,000 | +29987.5% | 31,764 | +63428.0% | 0.02% | – |
| Q2 2021 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2021 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q3 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q2 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q3 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q2 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2019 | $8,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |